210 related articles for article (PubMed ID: 15580378)
21. Inflammation-related aberrant patterns of DNA methylation: detection and role in epigenetic deregulation of cancer cell transcriptome.
Suzuki H; Toyota M; Kondo Y; Shinomura Y
Methods Mol Biol; 2009; 512():55-69. PubMed ID: 19347273
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
23. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection.
Hoque MO; Begum S; Topaloglu O; Chatterjee A; Rosenbaum E; Van Criekinge W; Westra WH; Schoenberg M; Zahurak M; Goodman SN; Sidransky D
J Natl Cancer Inst; 2006 Jul; 98(14):996-1004. PubMed ID: 16849682
[TBL] [Abstract][Full Text] [Related]
24. [Alterations of the p16 gene for the carcinogenesis in pancreas].
Wang C; Lu X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Oct; 22(5):491-3. PubMed ID: 12903437
[TBL] [Abstract][Full Text] [Related]
25. Dormant hypermethylated tumour suppressor genes: questions and answers.
Esteller M
J Pathol; 2005 Jan; 205(2):172-80. PubMed ID: 15643671
[TBL] [Abstract][Full Text] [Related]
26. Quantitative analysis of NPTX2 hypermethylation is a promising molecular diagnostic marker for pancreatic cancer.
Park JK; Ryu JK; Lee KH; Lee JK; Yoon WJ; Lee SH; Yoo JW; Woo SM; Lee GY; Lee CH; Kim YT; Yoon YB
Pancreas; 2007 Oct; 35(3):e9-15. PubMed ID: 17895837
[TBL] [Abstract][Full Text] [Related]
27. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results.
Digel W; Lübbert M
Crit Rev Oncol Hematol; 2005 Jul; 55(1):1-11. PubMed ID: 15886007
[TBL] [Abstract][Full Text] [Related]
28. Aberrant promoter hypermethylation in biliary tract carcinoma.
Kohya N; Koga Y; Kitajima Y; Miyazaki K
J Hepatobiliary Pancreat Surg; 2006; 13(4):296-305. PubMed ID: 16858540
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
Baylin SB; Ohm JE
Nat Rev Cancer; 2006 Feb; 6(2):107-16. PubMed ID: 16491070
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients.
Taback B; Giuliano AE; Lai R; Hansen N; Singer FR; Pantel K; Hoon DS
Ann N Y Acad Sci; 2006 Sep; 1075():211-21. PubMed ID: 17108214
[TBL] [Abstract][Full Text] [Related]
32. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
[TBL] [Abstract][Full Text] [Related]
33. Review of genetic and epigenetic alterations in hepatocarcinogenesis.
Herath NI; Leggett BA; MacDonald GA
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):15-21. PubMed ID: 16706806
[TBL] [Abstract][Full Text] [Related]
34. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
35. Predicting favourable prognosis of urothelial carcinoma: gene expression and genome profiling.
van der Kwast TH; Bapat B
Curr Opin Urol; 2009 Sep; 19(5):516-21. PubMed ID: 19553819
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic changes in cancer and preneoplasia.
Herman JG
Cold Spring Harb Symp Quant Biol; 2005; 70():329-33. PubMed ID: 16869769
[TBL] [Abstract][Full Text] [Related]
37. Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.
Chim CS; Wong KY; Loong F; Lam WW; Srivastava G
Hum Pathol; 2007 Dec; 38(12):1849-57. PubMed ID: 17900658
[TBL] [Abstract][Full Text] [Related]
38. [Molecular changes in development and progression of urothelial carcinoma].
Hartmann A
Verh Dtsch Ges Pathol; 2003; 87():172-84. PubMed ID: 16888910
[TBL] [Abstract][Full Text] [Related]
39. Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma.
Sato N; Fukushima N; Matsubayashi H; Iacobuzio-Donahue CA; Yeo CJ; Goggins M
Cancer; 2006 Jul; 107(2):251-7. PubMed ID: 16752411
[TBL] [Abstract][Full Text] [Related]
40. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective.
Sakorafas GH; Tsiotou AG; Tsiotos GG
Cancer Treat Rev; 2000 Feb; 26(1):29-52. PubMed ID: 10660490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
